(Q28188518)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16112972%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

title

The HOPE (Heart Outcomes Prevention Evaluation) Study and its consequences (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16112972%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16112972%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

author name string

McQueen MJ

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16112972%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

Lonn E

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16112972%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

Bosch J

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16112972%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

Yusuf S

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16112972%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

language of work or name

English

0 references

publication date

1 January 2005

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16112972%20AND%20SRC:MED&resulttype=core&format=json

The Scandinavian journal of clinical & laboratory investigation. Supplementum

5 January 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16112972%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

volume

240

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16112972%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

page(s)

143-156

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16112972%20AND%20SRC:MED&resulttype=core&format=json

Effects of long-term treatment with angiotensin-converting-enzyme inhibitors in the presence or absence of aspirin: a systematic review

5 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1080/00365510500236366

Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS).

21 April 2017

1 reference

https://api.crossref.org/works/10.1080%2F00365510500236366

Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365510500236366

Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365510500236366

Emerging role of angiotensin-converting enzyme inhibitors in cardiac and vascular protection

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365510500236366

Beyond cholesterol. Modifications of low-density lipoprotein that increase its atherogenicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365510500236366

Vitamin E consumption and the risk of coronary disease in women.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365510500236366

Vitamin E consumption and the risk of coronary heart disease in men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365510500236366

The antioxidant vitamins and cardiovascular disease. A critical review of epidemiologic and clinical trial data

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365510500236366

Study design and baseline characteristics of the study to evaluate carotid ultrasound changes in patients treated with ramipril and vitamin E: SECURE.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365510500236366

Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365510500236366

Effects of ramipril on coronary events in high-risk persons: results of the Heart Outcomes Prevention Evaluation Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365510500236366

Blood-pressure reduction and cardiovascular risk in HOPE study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365510500236366

Effects of ramipril and vitamin E on atherosclerosis: the study to evaluate carotid ultrasound changes in patients treated with ramipril and vitamin E (SECURE).

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365510500236366

Effect of long-term therapy with ramipril in high-risk women

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365510500236366

Gender differences in clinical trials in coronary heart disease: response to drug therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365510500236366

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365510500236366

Does aspirin attenuate the beneficial effects of angiotensin-converting enzyme inhibition in heart failure?

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365510500236366

Impact of ramipril in patients with evidence of clinical or subclinical peripheral arterial disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365510500236366

Comparative effects of ramipril on ambulatory and office blood pressures: a HOPE Substudy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365510500236366

Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365510500236366

Reversal of left ventricular hypertrophy in essential hypertension. A meta-analysis of randomized double-blind studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365510500236366

Reduction of cardiovascular risk by regression of electrocardiographic markers of left ventricular hypertrophy by the angiotensin-converting enzyme inhibitor ramipril

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365510500236366

Effects of ramipril on left ventricular mass and function in cardiovascular patients with controlled blood pressure and with preserved left ventricular ejection fraction: a substudy of the Heart Outcomes Prevention Evaluation (HOPE) Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365510500236366

Effect of ramipril in reducing sudden deaths and nonfatal cardiac arrests in high-risk individuals without heart failure or left ventricular dysfunction

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365510500236366

Prevention of Heart Failure in Patients in the Heart Outcomes Prevention Evaluation (HOPE) Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365510500236366

Cardiovascular risk in patients with early renal insufficiency: implications for the use of ACE inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365510500236366

Effects of vitamin E on cardiovascular outcomes in people with mild-to-moderate renal insufficiency: results of the HOPE study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365510500236366

Renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril: the HOPE randomized trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365510500236366

Progression of renal insufficiency in type 2 diabetes with and without microalbuminuria: results of the Heart Outcomes and Prevention Evaluation (HOPE) randomized study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365510500236366

Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365510500236366

Development of renal disease in people at high cardiovascular risk: results of the HOPE randomized study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365510500236366

Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365510500236366

Effects of vitamin E on cardiovascular and microvascular outcomes in high-risk patients with diabetes: results of the HOPE study and MICRO-HOPE substudy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365510500236366

Ramipril and the development of diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365510500236366

Virus-induced atherosclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365510500236366

Multiple infections and subsequent cardiovascular events in the Heart Outcomes Prevention Evaluation (HOPE) Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365510500236366

Relationship of anti-60 kDa heat shock protein and anti-cholesterol antibodies to cardiovascular events

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365510500236366

Biomarkers of endothelial dysfunction and risk of type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365510500236366

Cost implications of the use of ramipril in high-risk patients based on the Heart Outcomes Prevention Evaluation (HOPE) study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365510500236366

Economic impact of ramipril on hospitalization of high-risk cardiovascular patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365510500236366

Cost effectiveness of ramipril treatment for cardiovascular risk reduction

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365510500236366

The cost-effectiveness of ramipril in the treatment of patients at high risk of cardiovascular events: a Swedish sub-study to the HOPE study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365510500236366

Pathophysiologic and therapeutic importance of tissue ACE: a consensus report

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365510500236366

Rationale and Design of a Large Study to Evaluate the Renal and Cardiovascular Effects of an ACE Inhibitor and Vitamin E in High-Risk Patients With Diabetes: The MICRO-HOPE Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365510500236366

The Effect of Vitamin E Supplementation on Cardiovascular Risk in Diabetic Individuals With Different Haptoglobin Phenotypes

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365510500236366

Mechanisms of cardiovascular risk reduction with ramipril: insights from HOPE and HOPE substudies

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365510500236366

10.1080/00365510500236366

21 January 2018

Identifiers

DOI

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/diqnwt432rhlflmbjznmrnf3hq

mapped directly with Wikidata item

30 July 2022

based on heuristic

Fatcat ID

release_diqnwt432rhlflmbjznmrnf3hq

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/diqnwt432rhlflmbjznmrnf3hq

mapped directly with Wikidata item

30 July 2022

based on heuristic

1 reference

https://api.fatcat.wiki/v0/release/diqnwt432rhlflmbjznmrnf3hq